Merck Sharp + Dohme Corp.

Sunesis Pharmaceuticals, Inc.

Zhi-Qiang Yang

James C Barrow

Scott D Kuduk

Thomas S Reger

Youheng Shu

Kelly-Ann S Schlegel

Douglas C Beshore

Harold G Selnick

Craig Alan Coburn

Paul J Coleman

Melissa S Egbertson

Shaun R Stauffer

Wenjin Yang

Philippe G Nantermet

Lou Anne Neilson

Abbas M Walji

Kenneth E Rittle

Melody McWherter

Georgia B McGaughey

Christina Ng DiMarco

Wanli Lu

Bruce Fahr

Constantine Kreatsoulas

Hong Zhu

Yoheng Shu

Rowena V Cube

Daniel Pitts

Christina Ng Dimarco

Mamio Christa Merck & Co Inc Mattern

Kelly-Ann S Merck & Co Inc Bieber

Georgia B Mcgaughey

Melody A Mcwherter

The present invention is directed to N-linked lactam compounds of general formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor. 

N-linked lactam M1 receptor positive allosteric mogulators

The present invention is directed to quinoline amide compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor. 

Quinoline amide M1 receptor positive allosteric modulators

The present invention is directed to certain Oxazole derivatives which are useful as modulators of Fatty Acid Amide Hydrolase (FAAH) and as FAAH imaging agents. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzheimer Disease, and Parkinson's Disease.

Oxazole derivatives useful as modulators of FAAH

The present invention is directed to heterocycle amide compounds which are antagonists of T-type calcium channels, and which are useful in the treatment or prevention of disorders and diseases in which T-type calcium channels are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which T-type calcium channels are involved.

Heterocycle amide T-type calcium channel antagonists

The present invention is directed to N-linked quinoline amide compounds of general formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor. 

N-linked quinolineamide M1 receptor positive allosteric modulators

The present invention is directed to isoindolone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor. 

Isoindolone M1 receptor positive allosteric modulators

The present invention is directed to heterocycle phenyl amide compounds which are antagonists of T-type calcium channels, and which are useful in the treatment or prevention of disorders and diseases in which T-type calcium channels are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which T-type calcium channels are involved. 

Heterocycle phenyl amide T-type calcium channel antagonists

The present invention is directed to pyridyl amide compounds which are antagonists of T-type calcium channels, and which are useful in the treatment or prevention of disorders and diseases in which T-type calcium channels are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which T-type calcium channels are involved.

Pyridyl amide T-type calcium channel antagonists

The present invention is directed to spiropiperidine compounds of formula (I) which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.

Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease

Growing community of inventors

Schwenksville, PA, United States of America

Zhi-Qiang Yang